Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (839)	3/24/1998 8:38:00 PM
From: astro	Read Replies (2) \| Respond to of 1826

It would be nice to start another info ONLY tread to post previous technical info/reports and links (in as much as can be expected), chronological order. It would make it easier to reference here for discussion and for FAQs. Any suggestions, comments, volunteers? I think there are going to be more visitors here soon :). Lets shrink some tumors! astro

To: Russian Bear who wrote (839)	3/25/1998 9:28:00 AM
From: David Cathcart	Respond to of 1826

Bear, << Congratulations on the timing of your prediction.>> Thanks. This is actually a little earlier than I expected and I'm not sure what to make of it. We can't expect this linear rise to go on forever without some substance coming to the surface. Richard Dean Bagnell and I have said all along that MGI 114 warrants the attention of big pharma and that is perhaps what is happening now. It is anybody's guess though. Interesting times. This does feel good, double digits will feel better. Go MOGN! David

To: Russian Bear who wrote (839)	3/27/1998 9:13:00 AM
From: WTDEC	Read Replies (1) \| Respond to of 1826

Good morning RB. Here is the text of the news release: Friday March 27, 7:30 am Eastern Time Company Press Release SOURCE: MGI Pharma, Inc. MGI Pharma Announces Presentation of Data on its Novel Anti-Cancer Compound MGI 114 at the American Association for Cancer Research Meeting, March 28-April 1, 1998 MINNEAPOLIS, March 27 /PRNewswire/ -- At the Eighty-Ninth Meeting of the American Association of Cancer Research (AACR), opening tomorrow in New Orleans, four preclinical studies with MGI 114, a potential new anti-cancer compound, will be presented showing the drug's efficacy against tumor cell lines alone and in combination with several leading chemotherapy drugs. MGI PHARMA, INC. (Nasdaq: MOGN - news), a Minneapolis-based pharmaceutical company, is developing MGI 114, which is currently in Phase I human clinical studies. Charles N. Blitzer, MGI PHARMA's president and chief executive officer, said: ''We're pleased to have this preclinical data presented at AACR providing additional evidence that MGI 114 has the potential to be an exciting anti-cancer product. Previously published animal studies have shown MGI 114 to be effective against a variety of solid human tumors when transplanted to mice, including breast, colon and lung. We look forward to continuing our current development efforts with the drug to see if it can be proven to be as effective in humans as it has shown to be in animals.'' The papers to be presented on MGI 114 at AACR include two studies showing the drug's effect on leukemic cell lines and two papers showing MGI 114's ability to combine effectively with other chemotherapy agents to kill or inhibit the growth of human colon and pediatric tumor cell lines. Sunday, March 29: Maryanne Herzig, Ph.D. will discuss her laboratory study focused on identifying the drug's mechanism of antitumor action. This study showed that CEM leukemic cells rapidly accumulate MGI 114 with intracellular binding to protein and DNA targets. Monday, March 30: Michael Kelner, M.D., will present animal study data showing MGI 114's ability to markedly inhibit myeloid leukemia tumor growth compared to several conventional antitumor agents. Tuesday, March 31: Two studies conducted under the direction of Steven Weitman, M.D., Ph.D., will be presented. The first study demonstrates that a combination of MGI 114 with either the topoisomerase I inhibitor irinotecan (ITN) or 5-fluorouracil (5-FU) produces a better response in human colon tumors transplanted to mice than that produced by the agents alone. The second study demonstrates the additive or synergistic effect of MGI 114 on pediatric tumor cell lines when combined with cytotoxic agents, such as topotecan, paclitaxel, cisplatin, etoposide or gemcitabine. MGI PHARMA is a pharmaceutical company, headquartered in Minnetonka, Minn., that acquires, develops and markets innovative products for niche medical markets of umnet medical need. The company currently markets Salagen(R) Tablets (pilocarpine hydrochloride), INFeD(R) (iron dextran injection 50mg/ml) and Didronel(R) I.V. Infusion (etidronate disodium) in the United States. This press release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the company and its management. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause the company's actual results to differ materially from the results discussed in these statements. Factors that might cause such differences include, but are not limited to, the ability of MGI 114 to be proven safe and effective in humans as a chemotherapy agent, and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission. SOURCE: MGI Pharma, Inc. ------------------------------------------------------------------------